Hadasit Bio (HDST) - Cash Flow Conversion Efficiency

Latest as of June 2022: -0.009x

Based on the latest financial reports, Hadasit Bio (HDST) has a cash flow conversion efficiency ratio of -0.009x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-360.50K ≈ $-966.49 USD) by net assets (ILA39.81 Million ≈ $106.73K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hadasit Bio - Cash Flow Conversion Efficiency Trend (2013–2022)

This chart illustrates how Hadasit Bio's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hadasit Bio total liabilities for a breakdown of total debt and financial obligations.

Hadasit Bio Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hadasit Bio ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
UIL Ltd
LSE:UTL
0.057x
PBS Finanse SA
WAR:PBF
-0.096x
Jadestone Energy Inc
LSE:JSE
-0.014x
WINDFALL GEOTEK
F:L7C2
-0.801x
Sungmoon Electronics Co Ltd
KO:014915
0.037x
Stinger Resources Inc
V:STNG
-0.044x
Key Alliance Group Bhd
KLSE:0036
1.245x
Lucapa Diamond Co Ltd
F:NHY
-0.007x

Annual Cash Flow Conversion Efficiency for Hadasit Bio (2013–2022)

The table below shows the annual cash flow conversion efficiency of Hadasit Bio from 2013 to 2022. For the full company profile with market capitalisation and key ratios, see market value of Hadasit Bio.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2022-12-31 ILA35.08 Million
≈ $94.04K
ILA-2.12 Million
≈ $-5.67K
-0.060x -88.52%
2021-12-31 ILA65.69 Million
≈ $176.12K
ILA-2.10 Million
≈ $-5.63K
-0.032x +70.05%
2020-12-31 ILA37.11 Million
≈ $99.49K
ILA-3.96 Million
≈ $-10.62K
-0.107x +81.53%
2019-12-31 ILA5.50 Million
≈ $14.75K
ILA-3.18 Million
≈ $-8.53K
-0.578x -20.50%
2018-12-31 ILA34.30 Million
≈ $91.96K
ILA-16.46 Million
≈ $-44.12K
-0.480x -65.93%
2017-12-31 ILA60.79 Million
≈ $162.97K
ILA-17.57 Million
≈ $-47.12K
-0.289x -21.36%
2016-12-31 ILA61.62 Million
≈ $165.20K
ILA-14.68 Million
≈ $-39.36K
-0.238x -8.35%
2015-12-31 ILA60.30 Million
≈ $161.66K
ILA-13.26 Million
≈ $-35.55K
-0.220x +60.29%
2014-12-31 ILA22.11 Million
≈ $59.28K
ILA-12.24 Million
≈ $-32.82K
-0.554x -18.68%
2013-12-31 ILA24.89 Million
≈ $66.72K
ILA-11.61 Million
≈ $-31.13K
-0.467x --

About Hadasit Bio

TA:HDST Israel Biotechnology & Medical Research
Market Cap
$2.16 Million
ILA803.92 Million ILA
Market Cap Rank
#29806 Global
#438 in Israel
Share Price
ILA72.50
Change (1 day)
+0.00%
52-Week Range
ILA28.10 - ILA83.00
All Time High
ILA2847.77
About

HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more